MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL
Medtronic Neuromodulation · Decision date Sep 29, 1997
What did the FDA approve?
FDA approved PMA P970004 on September 29, 1997, for the Medtronic InterStim Sacral Nerve Stimulation System. The approval covers the model 3886 or 3080 lead, model 7495 extension, model 7424 implantable pulse generator, model 7455 memory module, model 7432 console programmer, model 7452 control magnet, model 3625 test stimulator, model 3065U PNE kit, and accessories.
The stated indication is treatment of urinary urge incontinence in patients who have failed or could not tolerate more conservative treatments. The source statement reports this intended purpose but does not provide independent proof of safety or clinical effectiveness. The decision is an original PMA approval, not a supplement, and no supplement type or reason is recorded.
FDA approval order statement
APPROVAL FOR THE MEDTRONIC(R) INTERSTIM(R) SACRAL NEVE STIMULATION (SNS)(TM) SYSTEM WHICH INCLUDES THE MODEL 3886 OR 3080 LEAD, MODEL 7495 EXTENSION, MODEL 7424 IMPLANTABLE PULSE GENERATOR (IPG), MODEL 7455 MEMORY MODULE, MODEL 7432 CONSOLE PROGRAMMER, MODEL 7452 CONTROL MAGNET, MODEL 3625 TEST STIMULATOR (SCREENER), AND MODEL 3065U PNE KIT AND ACCESSORIES. THIS DEVICE IS INDICATED FOR THE TREATMENT OF URINARY URGE INCONTINENCE IN PATIENT WHO HAVE FAILED OR COULD NOT TOLERATE MORE CONSERVATIVE TREATMENTS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 29, 1997
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P970004
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- Decision code
- APPR
- Decision date
- Sep 29, 1997
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implantable, for incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P970004 received
Application receipt date recorded by FDA.
P970004 · FDA decision
APPR
P970004/S458 · Related supplement
InterStim Therapy System Verify Evaluation System
P970004/S457 · Related supplement
InterStim Therapy System, Verify Evaluation System
P970004/S459 · Related supplement
InterStim Therapy System, Verify Evaluation System
P970004/S460 · Related supplement
InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800), (SNS Urinary Neurostimulator I
Timeline entries are records held by MedtechLedger for P970004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P970004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


